Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Poseida Therapeutics

Evaluate

Thumbnail
November 18, 2022

Pulling back the curtain on Astrazeneca’s Car-T work

Astra’s stealthy move into cell therapy has yielded a truly novel cancer target, and the company could be in clinical trials soon.

Thumbnail
November 10, 2022

Ash 2022 preview – Argenx’s expansion plans come into focus

Vyvgart gets a prestigious press slot for its next potential use, while Sangamo’s haemophilia A gene therapy mimics Biomarin’s valrox again.

Article image
Vantage logo
August 03, 2022

It’s official: Roche is a Car-T player

Asset prices fall sufficiently to persuade Roche to sign up to Poseida’s allogeneic cell therapies.

Article image
Vantage logo
January 10, 2022

A late Christmas present for Allogene

US clinical hold over Allogene’s entire pipeline has just been lifted.

Article image
Vantage logo
December 15, 2021

Ash 2021 movers – IGM steals the show, for all the wrong reasons

At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.

Article image
Vantage logo
November 08, 2021

Ash 2021 preview – as competition grows Autolus monetises

Several cell therapy presentations will vie for attention at Ash, though today the spotlight falls on Autolus.

Article image
Vantage logo
October 13, 2021

Crispr’s reminder about allogeneic Car-T redosing

Crispr follows Allogene with backing for off-the-shelf Car-T therapy – and adds big concerns over lack of durability.

Article image
Vantage logo
October 08, 2021

Allogene raises the spectre of a Car-T nightmare

Little is known about yesterday’s clinical hold on Allogene’s entire pipeline, but chromosomal abnormalities hint at a worst-case scenario.

Article image
Vantage logo
July 28, 2021

Amgen doubles down on bispecifics, courtesy of Teneobio

Curiously, the $900m acquisition will not include many of Teneobio’s pipeline projects.

Article image
Vantage logo
April 16, 2021

Precision’s itinerant Car-T cells go on another journey

The company overhauls senior management as its lead technology continues being passed from pillar to post. What is going on?

Article image
Vantage logo
December 09, 2020

Ash 2020 movers – shorts roasting on an open fire

IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up